Venetoclax

SAN DIEGO — A treatment regimen of loncastuximab tesirine combined with venetoclax may be safe and effective in a subset of patients with non-Hodgkin lymphoma, according to early research presented at ASH Annual Meeting and Exposition.

SAN DIEGO — A multidrug combination significantly improved survival for certain patients with leukemia compared with standard chemoimmunotherapy, according to results of the randomized phase 3 AMPLIFY study.

Naval Daver, MD, spoke with Healio about updates in FLT3-mutated acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.

Healio spoke with Naval Daver, MD, about a debate on the best duration of venetoclax in combination with azacitidine among older patients with acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.

Enrollment for a randomized phase 2 trial designed to compare a triplet regimen and doublet regimen for certain patients with leukemia has been discontinued due to low likelihood of benefit.

In a video interview, Matthew Cortese, MD, MPH, discusses how AI could transform the treatment landscape for CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses the importance of long-term monitoring in CLL care.

In a video interview, Matthew Cortese, MD, MPH, discusses strategies to combat infections in CLL patients.

In a video interview, Matthew Cortese, MD, MPH, discusses advances in treatments for relapse/refractory CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses how to approach initial treatment of CLL.